# SAMURAI (NCT05327686)

> Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05327686
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: NRG Oncology
- Conditions: Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma
- Interventions: Avelumab; Axitinib; Biospecimen Collection; Bone Scan; Cabozantinib; Computed Tomography; Ipilimumab; Lenvatinib; Magnetic Resonance Imaging; Nivolumab; Pembrolizumab; Stereotactic Ablative Radiotherapy
- Enrollment: 240
- Primary outcome: Nephrectomy and radiographic progression-free survival (nrPFS)

## Indexed commentary on SAMURAI so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=samurai-nct05327686